



---

Quality & Excellence

---

## FD NeuroSilver™ Kit II

A rapid silver staining kit for the microscopic  
detection of neuronal damage

User Manual

PK 301/301A, Version 2008-01

FOR *IN VITRO* RESEARCH USE ONLY  
not for diagnostic or other uses

**FD NeuroTechnologies**  
Consulting & Services, Inc.

© 1997-2009 All Rights Reserved

## **Contents**

I.	Introduction	4
II.	Kit Contents	5
III.	Materials Required but Not Included	5
IV.	Safety and Handling Precautions	6
V.	Tissue Preparation	6
VI.	Staining Procedure	8
VII.	Evaluation of Results	11
VIII.	References using this kit	11

## I. Introduction

FD NeuroSilver™ Kit II, an improved FD NeuroSilver™ Kit I, is designed for the detection of degenerating neurons in fixed tissue sections of the central nervous system from experimental animals. The principle of this kit is based on the findings that certain components of neurons undergoing degeneration, such as lysosomes, axons and terminals, become particularly argyrophilic. Under certain conditions, these cellular elements bind to silver ions with high affinity. Upon reduction, the silver ions form metallic grains that are visible under a light or an electron microscope.

FD NeuroSilver™ Kit has been widely used in animal studies under various experimental conditions (cf. page 11 for references using this kit). This kit has proven extremely specific and sensitive for the detection of degenerating neuronal somata, axons and terminals in both the brain and the spinal cord. It is particularly useful for the detection of small numbers of degenerating neurons that may not be demonstrable with routine histopathological techniques (for photo samples, please visit our web site at [www.fднеurotech.com](http://www.fднеurotech.com)).

FD NeuroSilver™ Kit has also been proven to be very sensitive and reliable for the detection of amyloid plaques in the brains of transgenic mice. In addition, this kit may be used for demonstrating neurodegeneration and/or amyloid plaques in tissue sections that have been processed for immunohistochemistry (cf. Nature Neuroscience 3: 1301-1306, 2000).

## II. Kit Contents

### Store at room temperature

	<u>PK301A</u>	<u>PK301</u>
Solution A	250 ml	500 ml
Solution B	250 ml	500 ml
Solution C	250 ml x 2	500 ml x 2
Solution D	250 ml	500 ml
Solution E	1 ml	2 ml
Solution F	2 ml	3 ml
Solution G (10X)	250 ml	500 ml
Glass specimen retriever	2	2
Natural hair paintbrush	1	1
User Manual	1	1

## III. Materials Required but Not Included

1. Double distilled or Milli-Q water
2. 6-well tissue culture plates
3. (Optional) Corning<sup>®</sup> Netwells<sup>®</sup> inserts (Corning Cat. #3480) and carrier kit (Corning Cat. #3521)
4. Histological supplies and equipment:
  - Microscope slides and coverslips
  - Natural hair paintbrush
  - Staining jars
  - Xylenes or xylene substitutes
  - Resinous mounting medium (e.g. Permoumt<sup>®</sup>)
  - A light microscope.

Corning<sup>®</sup> & Netwells<sup>®</sup> are registered trademarks of Corning, Inc.  
Permoumt<sup>®</sup> is a registered trademark of Fisher Scientific.

## IV. Safety and Handling Precautions

1. FD NeuroSilver™ Kit II is made for *in vitro* research use only and not for drug, diagnostic or other uses.
2. The kit contains reagents that may be harmful in contact with skin or by inhalation and fatal if ingested. Do not pipette by mouth. Avoid inhalation and contact with skin and eyes. In case of contact, wash immediately with generous amounts of water and seek medical advice. If swallowed, wash out mouth with water and immediately call a physician.
3. Perform experiment under a chemical hood. **Wear suitable protective clothing, gloves and eye/face protection while handling kit reagents.** Wash hands thoroughly after performing the experiment.

## V. Tissue Preparation

### Note

*FD NeuroSilver™ Kit II has been proven to produce the best results in animal brain sections prepared according to the following procedure. However, it may be used in tissue specimens prepared differently (please contact FD NeuroTechnologies for more information).*

1. Experimental animals should be deeply anesthetized and perfused via the ascending aorta with saline for 1 minute followed by 0.1 M phosphate buffer (PB, pH 7.4) containing 4% paraformaldehyde.

hyde for 15 minutes (different species may require a different amount of perfusates, e.g. for a rat, 100 ml of saline and 500 ml of fixative should be sufficient). Upon removal, brains should be postfixed in the same fixative as that used for the perfusion at least overnight at 4°C. Subsequently, brains should be immersed in 0.1 M PB containing 20% sucrose for 48 hours at 4°C before freezing.

 **Note**

*If thick sections (e.g. above 60 µm) will be cut with a cryostat, we highly recommend the use of our tissue cryoprotection solution (Cat. #: PC102 ) instead of the sucrose solution.*

2. Sections of 40 – 80 µm thickness may be cut either on a cryostat\* or a vibratome (similar types of microtomes, such as a sliding microtome may be used alternatively). Sections should be collected in 0.1 M PB (pH 7.4) and be subsequently transferred into 0.1 M PB containing 4% paraformaldehyde. Store sections in 0.1 M PB containing 4% paraformaldehyde for at least 2 days at 4°C before processing with FD NeuroSilver™ kit II.

*\* To prevent tissue from ice crystal damage and to preserve the best possible cell morphology, tissue should be frozen rapidly before sectioning, e.g. by immersing the tissue in isopentane precooled to -70°C with dry ice.*

**ⓘ Warning**

*Paraformaldehyde is harmful and toxic to humans if ingested or inhaled. The experiment with paraformaldehyde should be performed under a chemical hood with appropriate protection. Wear glasses and disposable gloves.*

## **VI. Staining Procedure**

**The following instructions MUST be read before using this kit.**

- *All containers (plastic or glass) to be used should be clean and rinsed with distilled water.*
  - *Do not use metal implements in the procedure.*
  - *Prepare fresh working solutions and keep containers tightly closed at all times.*
  - *Use 0.8 ml of solution for each 2 cm<sup>2</sup> of the section (e.g. approximately a rat brain coronal section through the dorsal hippocampus) to be stained at each step.*
  - *Avoid bringing excess solution from one step to another.*
  - ***Very important!***
  - *Do not let sections dry up anytime before mounting them on slides.*
  - *Use of positive control sections is recommended for each experiment.*
  - *The following procedure takes approximately 1 hour and should be performed at room temperature.*
1. Rinse sections in double distilled or Milli-Q water 2 times, 5 minutes each.

2. Transfer sections into a mixture containing equal volumes of **Solutions A** and **B**, 2 times, 10 minutes each.

 **Note**

- Sections should be immersed in the solution and incubated free floating with gentle shaking.
  - The incubation plate must be covered during incubation to prevent vaporization of the reagent.
3. Place sections in a mixture consisting of equal volumes of **Solutions A** and **B** with **Solution E** (one drop of Solution E for each 8 ml of a total volume of Solutions A and B) for 10 minutes.

e.g.	<b>Solution A</b>	4 ml
	<b>Solution B</b>	4 ml
	<b>Solution E</b>	1 drop

 **Note**

- All 3 solutions must be well mixed and the resultant mixture should be totally clear without precipitates.
  - Sections should be immersed in the solution and incubated free floating with gentle shaking.
  - The incubation plate must be covered during incubation to prevent vaporization of the reagent.
4. Place sections in a mixture of **Solution C** and **Solution F** (one drop of Solution F for each 25 ml of Solution C), 2 times, 2 minutes each\*.

\* A total of 4 minutes of incubation time is satisfactory in most cases. However, variations in tissue processing may require that the duration of this step be lengthened (for decreasing the background stain) or shortened (for

increasing the staining intensity). Note that prolonging the time of incubation will also decrease or possibly eliminate specific silver staining.

 **Note**

- Sections should be *immersed* in the solution and incubated free floating with gentle shaking.
- The incubation plate must be covered during incubation to prevent vaporization of the reagent.

5. Place sections in a mixture of **Solution D** and **Solution F** (one drop of Solution F for each 25 ml of Solution D) for 5 minutes.

 **Note**

- Sections should be *immersed* in the solution and incubated free floating with gentle shaking.
- The incubation plate must be covered during incubation to prevent vaporization of the reagent.

6. Rinse sections in double distilled or Milli-Q water 2 times, 3 minutes each.
7. Place sections in 1x **Solution G** (10x concentrated solution provided, dilute with double distilled or Milli-Q water before use), 2 times, 5 minutes each.

 **Note**

- For the best results, keep sections in 1x Solution G for 1-2 hours before mounting.
- Silver-stained sections should be protected from light whenever possible.

8. Mount sections on pre-cleaned slides directly from 1x Solution G and let air-dry.

### **Note**

*For easy mounting, do not use adhesive microscope slides, including Superfrost Plus slides unless sections tend to fall off the slides during dehydration.*

9. Dehydrate sections in absolute alcohol, 2 times, 3 minutes each; clear in xylenes or xylene substitutes, 3 changes, 3 minutes each; and cover-slip in a resinous mounting medium (e.g. Permount<sup>®</sup>).

## **VII. Evaluation of Results**

Sections should be examined under a light microscope with either a brightfield or a darkfield condenser. Neurons undergoing degeneration are indicated by dense silver precipitates, appearing as black (brightfield) or golden (darkfield) grains, in their somata and/or processes. Photo samples are available at [www.fднеurotech.com](http://www.fднеurotech.com).

## **VIII. References using this kit:**

1. Wetzel MK, Naska S, Laliberté CL, Rymar VV, Fujitani M, Biernaskie JA, Cole CJ, Lerch JP, Spring S, Wang SH, Frankland PW, Henkelman RM, Josselyn SA, Sadikot AF, Miller FD, Kaplan DR. p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease. **Neuron** 59 (5):708-21, 2008.
2. Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. **J Neurochem** 106(5):2205-17, 2008.
3. Eid T, Ghosh A, Wang Y, Beckström H, Zaveri HP, Lee TS, Lai JC, Malthankar-Phatak GH, de Lanerolle NC. Recurrent seizures

and brain pathology after inhibition of glutamine synthetase in the hippocampus in rats. **Brain** 131(Pt 8):2061-70, 2008.

4. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. **Neurobiol Dis** 31(1):46-57, 2008.
5. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. **Neurobiol Dis** 30(3):293-302, 2008.
6. Jackson N, Muthuswamy J. Artificial dural sealant that allows multiple penetrations of implantable brain probes. **J Neurosci Methods** 171(1):147-52, 2008.
7. Calingasan NY, Ho DJ, Wille EJ, Campagna MV, Ruan J, Dumont M, Yang L, Shi Q, Gibson GE, Beal MF. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. **Neuroscience** 153(4):986-96, 2008.
8. Guilarte TR, Burton NC, Verina T, Prabhu VV, Becker KG, Syversen T, Schneider JS. Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. **J Neurochem** 105(5):1948-59, 2008.
9. Dombrowski SM, Deshpande A, Dingwall C, Leichliter A, Leibson Z, Luciano MG. Chronic hydrocephalus-induced hypoxia: increased expression of VEGFR-2+ and blood vessel density in hippocampus. **Neuroscience** 152(2):346-59, 2008.
10. Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. **PLoS ONE** 3(2):e1616, 2008.
11. Berman RF, Pessah IN, Mouton PR, Mav D, Harry J. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. **Toxicol Sci** 101(2):294-309, 2008.
12. Moussa CE, Rusnak M, Hailu A, Sidhu A, Fricke ST. Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies. **Exp Neurol** 209(1):224-33, 2008.
13. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. **J Neurosci** 28(2):425-33, 2008.
14. Flanagan-Cato LM, Fluharty SJ, Weinreb EB, LaBelle DR. Food restriction alters neuronal morphology in the hypothalamic ventromedial nucleus of male rats. **Endocrinology** 149(1):93-9, 2008.
15. Choi, Dong-Young, Hunter, Randy, Liu, Mei, Cass, Wayne, Pandya, Jignesh, Sullivan, Patrick, Shin, Eun-Joo, Kim, Hyoung-Chun, Gash, Don, and Bing, Guoying. Striatal neuroinflammation promotes parkinsonism in rats. Available from **Nature Pre-**

- cedings** <<http://hdl.handle.net/10101/npre.2008.1970.1>>, 2008.
16. Lehrmann E, Guidetti P, Löve A, Williamson J, Bertram EH, Schwarcz R. Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice. **Epilepsia** 49 Suppl 2:13-23, 2008.
  17. Parthasarathy KS, Cheng YC, McAllister JP 2nd, Shen Y, Li J, Deren K, Haacke EM, Auner GW. Biocompatibilities of sapphire and borosilicate glass as cortical neuroprostheses. **Magn Reson Imaging** 25(9):1333-40, 2007.
  18. Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, Wang Y, Chase TN, Bennett MC, Qin ZH. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. **Brain Res** 1145:190-203, 2007.
  19. Bliss RM, Hoffman T, Finckbone V, Zeitouni T, Mansouri B and Strahlendorf J. AMPA-induced excitotoxicity stimulates calpain activity and is exacerbated by tumor necrosis factor- $\alpha$ ; (TNF- $\alpha$ ) in the CA1 and CA3 regions of the hippocampus in an acute slice model. *The FASEB Journal* 21:943.2, 2007.
  20. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC and Miller GW. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. **J. Neuroscience** 27:8138-8148, 2007.
  21. Kaur D, Rajagopalan S, Chinta S, Kumar J, Monte DD, Cherny RA and Andersen JK. Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. **Brain Research** 1140:188-194, 2007.
  22. Setsuie R, Wang YL, Mochizuki H, Osaka H, Hayakawa H, Ichihara N, Li H, Furuta A, Sano Y, SunYJ, Kwon J, Kabuta T, Yoshimi K, Aoki S, Mizuno Y, Noda M and Wada K. Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 193M mutant. **Neurochemistry International** 50:119-129, 2007.
  23. Wang A, Liang X, McAllister II JP, Li J, Brabant K, Black C, Finlayson P, Cao T, Tang H, Salley SO, Auner GW and Simon Ng KY. Stability of and inflammatory response to silicon coated with a fluoroalkyl self-assembled monolayer in the central nervous system. **J. Biomed. Mater. Res. A** 81:363-372, 2007.
  24. Williams AJ, Wei HH, Dave JR and Tortella FC. Acute and delayed neuroinflammatory response following experimental penetrating ballistic brain injury in the rat. **J. Neuroinflammation** 4:17, 2007.
  25. Xu W, Wong TP, Chery N, Gaertner T, Wang YT and Baudry M. Calpain-mediated mGluR1 $\alpha$  truncation: A key step in excitotoxicity. **Neuron** 53:399-412, 2007.
  26. VJ, Lorenz JN, Dunn RS, Vorhees CV Wills-Karp M, Degen JL, Davis RJ, Mizushima N, Rakic P, Dardzinski BJ, Holland SK, Sharp FR and Kuan CY. Cerebral ischemia-hypoxia induces in

- travascular coagulation and autophagy. **American J. Pathology** 169:566-583, 2006.
27. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N and Krainc D. Transcriptional repression of PGC-1 $\alpha$  by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. **Cell** 127:59-69, 2006.
  28. Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, Park M, Smith K and Cannard K. Mefloquine induces dose-related neurological effects in a rat model. **Antimicrobial Agents & Chemotherapy** 50:1045-1053, 2006.
  29. Luo J, Lin AH, Masliah E and Wyss-Coray T. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. **Proc. Natl. Acad. Sci. USA** 103:18326-31, 2006.
  30. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL and Lee MK. Parkinson's disease  $\alpha$ -synuclein transgenic mice develop neuronal mice develop neuronal mitochondrial degeneration and cell death. **J. Neuroscience** 26:41-50, 2006.
  31. Rao MS, Hattiangady B, Reddy DS and Shetty AK. Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy. **J. Neurosci. Res.** 83:1088-1105, 2006.
  32. Saxon DW and White G. Episodic vestibular disruption following ablation of the inferior olive in rats: Behavioral correlates. **Behavioural Brain Research** 175:128-138, 2006.
  33. Saydoff JA, Garcia RAG, Browne SE, Liu LS, Sheng J, Brennehan D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H and Flint Beal M. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. **Neurobiol. Dis.** 24:455-465, 2006.
  34. Theodore S, Stolberg S, Cass WA and Maragos WF. Human immunodeficiency virus-1 protein Tat and methamphetamine interactions. **Ann. N.Y.Acad. Sci.** 1074:178-190, 2006.
  35. Williams AJ, Hartings JA, Lu XCM, Rolli ML and Tortella FC. Penetrating ballistic-like brain injury in the rat: differential time courses of hemorrhage, cell death, in lammation, and remote degeneration. **J. Neurotrauma** 23:1828-1846, 2006.
  36. Yan X, Benson JM, Gomez AP, Baden DG and Murray TF. Brevetoxin-induced neural insult in the retrosplenial cortex of mouse brain. **Inhalation Toxicology** 18:1109-1116, 2006.
  37. Yazdani U, German DC, Liang C-L, Manzano L, Sonsalla PK and Zeevalk GD. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). **Exp. Neurol.** 200:172-183, 2006.
  38. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR and Friedlander RM. Huntingtin inhibits caspase-3 activation. **EMBO Journal** 25:5896-5906, 2006.
  39. Liang ZQ, Wang XX, Wang Y, Chuang DM, DiFiglia M, Chase

- TN and Qin ZH. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. **Neurobiol. Dis.** 20:562-573, 2005.
40. Williams AJ, Hartings JA, LuXCM, Rolli ML, Dave JR and Tortella FC. Characterization of a new rat model of penetrating ballistic brain injury. **J. Neurotrauma** 22:313-331, 2005.
  41. Zsombok A, Toth Z and Gallyas F. Basophilia, acidophilia and argyrophilia of "dark" (compacted) neurons during their formation, recovery or death in an otherwise undamaged environment. **Journal of Neuroscience Methods** 142:145-152, 2005.
  42. Abdel-Rahman A, Abou-Donia SM, El-Masry EM, Shetty AK and Abou-Donia MB. Stress and combined exposure to low doses of pyridostigmine bromide, deet, and permethrin produce neurochemical and neuropathological alterations in cerebral cortex, hippocampus, and cerebellum. **J. Toxicol. Environ. Health Part A** 67:163-192, 2004.
  43. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T and Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an  $\alpha$ -synuclein rat model of Parkinson's disease. **Proc. Natl. Acad. Sci. USA** 101:17510-17515, 2004.
  44. Paschen W, Yatsiv I, Shoham S and Shoshami E. Brain trauma induces X-box protein 1 processing indicative of activation of the endoplasmic reticulum unfolded protein response. **J. Neurochem.** 88:983-992, 2004.
  45. Shoham S and Youdim MBH. Nutritional iron deprivation attenuates ainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration. **Ann. N.Y. Acad. Sci.** 1012:94-114, 2004.
  46. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B and Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentivi ral vector-mediated overexpression of alpha-synuclein. **Brain Pathol.** 13:364-372, 2003.
  47. Manning-Boğ AB, McCormack AL, Purisai MG, Bolin LM and Di Monte A.  $\alpha$ -synuclein overexpression protects against paraquat-induced neurodegeneration. **J. Neuroscience** 23:3095-3099, 2003.
  48. Shoham S, Bejar C, Kovalev E and Weinstock M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. **Exp. Neurol.** 184:1043-1052, 2003.
  49. Sherer TB, Kim JH, Betarbet R and Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and  $\alpha$ -synuclein aggregation. **Exp. Neurol.** 179:9-16, 2003.
  50. Abdel-Rahman A, Shetty AK and Abou-Donia MB. Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of gulf-war syndrome. **Neurobiol. Dis.** 10:306-326, 2002.

51. Bianco CL, Ridet JL, Schneider BL, Déglon N and Aebischer P.  $\alpha$ -synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. **Proc. Natl. Acad. Sci. USA** 99:10813-10818, 2002.
52. Ding Y, Yao B, Zhou Y, Park H, McAllister JP and Diaz FG. Prereperfusion flushing of ischemic territory: a therapeutic study in which histological and behavioral assessments were used to measure ischemia-reperfusion injury in rats with stroke. **J. Neurosurg.** 96:310-9, 2002.
53. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrinou J, O'Callaghan JP and Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. **Exp. Neurol.** 173:183-195, 2002.
54. Guo-Ross SX, Clark S, Montoya DA, Jones KH, Obenier J, Shetty AK, White AM, Blusztajn JK, Wilson WA and Swartzwelder HS. Prenatal choline supplementation protects against postnatal neurotoxicity. **J. Neuroscience** 22:RC195, 2002.
55. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA and Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. **Neurobiol. Dis.** 10:119-127, 2002.
56. Montoliu C, Humet M, Canales J-J, Burda J, Planells-Cases R, Sánchez-Baeza F, Carbonell T, Pérez-Payá E, Messeguer A, Ferrer-Montiel A and Felipe V. Prevention of in vivo excitotoxicity by a family of trialkylglycines, a novel class of neuroprotectants. **J. Pharmacol. Exp. Ther.** 301:29-36, 2002.
57. Tong W, Igarashi T, Ferriero DM and Noble LJ. Traumatic brain injury in the immature mouse brain: characterization of regional vulnerability. **Exp. Neurol.** 176:105-116, 2002.
58. Ding Y, McAllister JP, Yao B, Yan N and Canady AI. Neuron tolerance during hydrocephalus. **Neuroscience** 106:659-667, 2001.
59. Ding Y, McAllister JP, Yao B, Yan N and Canady AI. Axonal damage associated with enlargement of ventricles during hydrocephalus: a silver impregnation study. **Neurol. Res.** 23:581-587, 2001.
60. Ding Y, Yao B, Lai Q and McAllister JP. Impaired motor learning and diffuse axonal damage in motor and visual systems of the rat following traumatic brain injury. **Neurol. Res.** 23:193-202, 2001.
61. Freeman A, Ciliax B, Bakay R, Daley J, Miller RD, Keating G, Levey A and Rye D. Nigrostriatal collaterals to thalamus degenerate in Parkinsonian animal models. **Ann Neurol.** 50:321-329, 2001.
62. Liu ZP, Gastard M, Verina T, Bora S, Mouton PR and Koliatsos VE. Estrogens modulate experimentally induced apoptosis of granule cells in the adult hippocampus. **J. Comp. Neurol.** 441:1-8, 2001.

63. Northington FJ, Ferriero DM, Graham EM, Traystman RJ and Martin LJ. Early neurodegeneration after hypoxia-ischemia in neonatal rat is necrosis while delayed neuronal death is apoptosis. **Neurobiol. Dis.** 8:207-219, 2001.
64. Northington FJ, Ferriero DM and Martin LJ. Neurodegeneration in the thalamus following neonatal hypoxia-ischemia is programmed cell death. **Dev. Neurosci.** 23:186-191, 2001.
65. Shoham S, Javitt DC and Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. **Biol. Psychiatry** 49:876-885, 2001.
66. Zito MA, Koennecke LA, McAuliffe MJ, McNally B, van Rooijen N and Heyes MP. Depletion of systemic macrophages by liposome-encapsulated clodronate attenuates striatal macrophage invasion and neurodegeneration following local endotoxin infusion in gerbils. **Brain Res.** 892:13-26, 2001.
67. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. **Nature Neuroscience** 3:1301-1306, 2000.
68. Kuhlmann AC and Guilarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. **J. Neurochem.** 74:1694-1704, 2000.
69. Sternfeld M, Shoham S, Klein O, Flores-Flores C, Evron T, IdelsoGH, Kitsberg D, Patrick JW and Soreq H. Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates. **Proc. Natl. Acad. Sci. USA** 97:8647-8652, 2000.
70. Ahima RS, Bjorbaek C, Osei S and Flier JS. Regulation of neuronal and glial proteins by leptin: implications for brain development. **Endocrinology** 140:2755-2762, 1999.
71. Burns LH, Jin Z and Bowersox SS. The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. **J. Vasc. Surg.** 30:334-343, 1999.

**For more references, please visit our website at [www.fdnurotech.com](http://www.fdnurotech.com).**

## Notes

---

## Notes

---

## Notes

---